ArticleCurrent geriatrics reports2019
Pharmacologic Management of Agitation in Patients with Dementia.
Article in Current geriatrics reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Comparative Effectiveness of Antidepressants and Second-Generation Antipsychotics for Agitation Among Nursing Home Residents with Dementia.Journal of general internal medicine · 2026Article
- Brexpiprazole for Agitation in Patients with Alzheimer's Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term Trials.Neuropsychiatric disease and treatment · 2026Article
- Review
- Behavioral and Psychological Symptoms (BPSD) in Alzheimer's Disease (AD): Development and Treatment.Current topics in behavioral neurosciences · 2025Review
- Effects of Electroconvulsive Therapy on Functional Outcomes Among Medicare Patients With Comorbid Depression and Dementia: A Nationwide 1-Year Follow-Up Study.The Journal of clinical psychiatry · 2023Article
- Characterizing PRN Use of Psychotropic Medications for Acute Agitation in Canadian Long-Term Care Residents with Dementia Before and During COVID-19.Journal of Alzheimer's disease reports · 2023Article
- Multi-dimensional relationships among dementia, depression and prescribed drugs in England and Wales hospitals.BMC medical informatics and decision making · 2022Article
- Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease.Neuronal signaling · 2022Review
- Staff Reports of Behavioral Expressions of Persons With Dementia in 250 Assisted Living Communities.The Gerontologist · 2022Article
- Gender Differences in Demographic and Pharmacological Factors in Patients Diagnosed with Late-Onset of Alzheimer's Disease.Brain sciences · 2022Article
- Exploring the Recent Trends in Management of Dementia and Frailty: Focus on Diagnosis and Treatment.Current medicinal chemistry · 2022Article
- Demographics and Medication Use of Patients with Late-Onset Alzheimer's Disease in Hong Kong.Journal of Alzheimer's disease : JAD · 2022Article
- Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Medications in Patients with Dementia and Behavioral Disturbance.Journal of Alzheimer's disease reports · 2021Article
- Agitation in Dementia: Real-World Impact and Burden on Patients and the Healthcare System.Journal of Alzheimer's disease : JAD · 2021Article
- Blood DNA Methylation Levels in the WNT5A Gene Promoter Region: A Potential Biomarker for Agitation in Subjects with Dementia.Journal of Alzheimer's disease : JAD · 2021Article
- Delirium Tremens in the Older Adult.The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses · 2020Article
- What the COVID-19 pandemic entails for the management of patients with behavioral and psychological symptoms of dementia: experience in France.International psychogeriatrics · 2020Article
- Cognitive Impairment Evaluation and Management.The Medical clinics of North America · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
purpose of reviewAgitation is common among older adults with dementia; its origin may be multi-factorial, and it is often difficult to treat. In this paper, we summarize current knowledge and offer considerations on pharmacologic management of behavioral and psychological symptoms of dementia (BPSD). RECENT
findingsWe reviewed human studies published from 2013 to 2018 evaluating pharmacologic management of BPSD manifestations including depressive symptoms, mania, psychosis, and other BPSD, as well as severe agitation without determination of underlying cause. After non-pharmacological management is exhausted, the choice of pharmacological options depends on patient comorbidities, specific BPSD presentation, and patient tolerance of medications. SUMMARY: Depending on manifestations of BPSD, low- to moderate-quality evidence supports the use of anti-depressants, anti-psychotics, or anti-epileptics in conjunction with cholinesterase inhibitors. The current evidence base needs to be augmented with future research that focuses on real-world medication use alongside head-to-head evaluation of medication effectiveness rather than comparison to placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.